Innovate UK

Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.

Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

ExplantLab is an independent research organization located in Newcastle upon Tyne, United Kingdom. The company focuses on exploring the connections between patient genetics and the design, manufacture, and performance of medical devices. By integrating genetic insights into its research, ExplantLab aims to enhance the effectiveness and safety of medical devices, ultimately improving the quality of life for patients.

Gendius Ltd. is a UK-based company founded in 2011 by Chris Genders and Rory Cameron, dedicated to improving the management of diabetes. The company has developed Intellin, an app-based platform designed to assist individuals living with diabetes by utilizing their clinical history to identify personal high-risk areas for complications. Intellin focuses users on clinically validated tasks and measures aimed at slowing the progression of these risks. Through its innovative approach, Gendius aims to enhance the quality of life for those affected by diabetes by providing tailored support and guidance.

Freeline Therapeutics is a clinical-stage biotechnology company focused on developing liver-directed gene therapies for bleeding disorders and other diseases. Based in Stevenage, United Kingdom, Freeline's lead product candidate, FLT180a, is undergoing Phase 1/2 clinical trials aimed at treating moderate to severe hemophilia B. The company's pipeline also includes FLT190, which is in dose-escalating Phase 1/2 trials for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A. Freeline utilizes a next-generation proprietary adeno-associated virus (AAV) vector platform, enhancing its potential for systemic gene therapy applications. Since its founding in 2015, the company has been dedicated to advancing innovative treatments in the field of gene therapy.

The Cell and Gene Therapy Catapult is a centre of excellence in innovation, with the core purpose of building a world-leading cell and gene therapy sector in the UK as a key part of a global industry. Supported by Innovate UK, their mission is to drive the growth of the industry by helping cell and gene therapy organisations across the world translate early stage research into commercially viable and investable therapies. They are based on the 12th floor of Guy’s Hospital in central London, with over 120 cell and gene therapy experts, state-of-the art development and viral vector laboratories. They are also building a £55m large-scale GMP manufacturing centre to help bring cell and gene therapies to market in the UK and internationally.

IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.

Mendelian is a company focused on accelerating the diagnosis of rare genetic diseases. By utilizing an intelligent agent, Mendelian analyzes patients' clinical features to identify the genes responsible for rare conditions. Physicians input phenotypic details, and the platform generates outputs that indicate potential causative genes and mutations. This innovative approach enhances the investigation of undiagnosed cases, allowing for earlier detection and treatment of rare diseases through machine learning and knowledge reasoning.

PepGen is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing the delivery of nucleic acid therapeutics, particularly antisense oligonucleotides. Established in 2018, PepGen aims to enhance the clinical efficacy of these therapeutics through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. This innovative technology employs engineered peptides designed for optimized tissue penetration, cellular uptake, and nuclear delivery, enabling effective transport of oligonucleotides to various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. By leveraging its drug delivery capabilities, PepGen seeks to transform the treatment landscape for severe neuromuscular and neurological diseases.

Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, established in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. By employing novel techniques, Evonetix aims to synthesize DNA with higher accuracy and scale, which enhances accessibility for researchers. This platform enables scientists to utilize synthetic biology on a previously unattainable scale, fundamentally changing how DNA is accessed, produced, and utilized for gene synthesis. The engineering team at Evonetix boasts extensive experience in creating high-integrity automated systems, bringing together a diverse range of expertise from various scientific and engineering disciplines to support its mission.

Eagle Genomics Ltd. specializes in providing data management and analysis solutions for the healthcare, pharmaceutical, biotech, and personal care sectors. Founded in 2008 and based in Cambridge, United Kingdom, with additional offices in the United States, Germany, and India, the company focuses on the management and analysis of genomic data, particularly through next-generation sequencing technologies. Its services encompass NGS data management, analysis, visualization, biomarker discovery, and custom software development. The company also offers pipeline design services and a web-based platform, ElasticAP, for managing life sciences research and development data in the cloud. With a unique blend of expertise in biology, bioinformatics, data science, and software engineering, Eagle Genomics helps clients in drug development, personal hygiene, and agri-tech industries maximize the value of their research and development data, addressing challenges associated with the increasing volume of life sciences data.

Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research, development and manufacture. Gene therapy is the treatment of disease by delivering therapeutic DNA into a patient’s cells. This can be either in vivo or ex vivo, the latter encompassing the field of cell therapy whereby genetically modified cells are put back into the body. Their pipeline of seven gene and cell therapy therapy products addresses diseases for which there is currently no treatment or that are inadequately treated today, including ocular and central nervous system disorders. Their product candidates have the potential to transform treatment landscapes. Their strategy is to develop their product candidates to their next value inflection points whilst continuing to build OXB Solutions into a valuable revenue-generating manufacturing and development services business.

Touchlight Genetics Ltd. is a biotechnology company based in Leatherhead, United Kingdom, focused on DNA therapies and technology. Founded in 2008, the company has developed the proTL synthetic DNA platform, which enables the production of doggybone closed linear DNA without the need for bacterial fermentation. This innovative approach serves various applications including veterinary vaccines, monoclonal antibodies, gene therapy, allergy treatment, RNA interference therapies, and stem cell reprogramming. Touchlight has assembled a skilled team of scientists and drug development experts, led by founder and CEO Jonny Ohlson, who is supported by a dynamic management team. The company has formed strategic collaborations with prestigious academic institutions such as Imperial College London and the University of Pennsylvania, contributing to the advancement of its technologies and the establishment of therapeutic proof-of-principle.

Eagle Genomics Ltd. specializes in providing data management and analysis solutions for the healthcare, pharmaceutical, biotech, and personal care sectors. Founded in 2008 and based in Cambridge, United Kingdom, with additional offices in the United States, Germany, and India, the company focuses on the management and analysis of genomic data, particularly through next-generation sequencing technologies. Its services encompass NGS data management, analysis, visualization, biomarker discovery, and custom software development. The company also offers pipeline design services and a web-based platform, ElasticAP, for managing life sciences research and development data in the cloud. With a unique blend of expertise in biology, bioinformatics, data science, and software engineering, Eagle Genomics helps clients in drug development, personal hygiene, and agri-tech industries maximize the value of their research and development data, addressing challenges associated with the increasing volume of life sciences data.

Oxford Genetics Ltd. is a UK-based synthetic biology company that focuses on DNA design, protein expression optimization, and cell line development technologies. The company specializes in producing versatile cloning plasmids for academic and biotechnology research, including offerings such as CRISPR plasmids, reporter genes, and various DNA constructs tailored for different purposes. In addition to its plasmid products, Oxford Genetics provides custom cloning and DNA synthesis services, all free of intellectual property restrictions. The company distributes its products through a network of distributors in multiple countries and also offers an online purchasing platform for customers. Founded in 2011 and headquartered in Begbroke, Oxford Genetics has formed a strategic partnership with The Native Antigen Company Ltd. to enhance its service offerings.

Genomics PLC is focused on advancing the use of genomic data to transform healthcare. The company develops algorithms and software solutions that facilitate the analysis of large genomic and phenotypic datasets, aimed at understanding human biology and improving disease diagnosis and treatment. Its offerings serve a diverse range of clients, including governments, healthcare providers, pharmaceutical companies, and research laboratories. By providing tools that enhance the accuracy of genetic analysis, Genomics PLC helps de-risk the drug development process and enables clinicians to better identify individuals at risk for specific diseases. Founded in 2014 and based in Oxford, United Kingdom, the company aims to set standards in genomic data application, ultimately benefiting organizations and patients alike through innovative healthcare solutions.

Isogenica Limited is a biotechnology company based in Little Chesterford, United Kingdom, that specializes in designing and licensing synthetic antibody libraries and display technologies for antibody discovery. The company offers several systems, including the llamdA System for single-domain antibodies, the Xab System for human antibody fragments, and the 4D Fab System for synthetic human antibodies. Additionally, Isogenica provides peptide and scaffold platforms to facilitate the development of therapeutic peptides aimed at treating diseases. Its proprietary vitro display technology, known as CIS display, is employed to discover biologically active peptides, proteins, and antibodies. The company's innovative small-format antibodies can be utilized to create bispecific and multi-specific biotherapeutics, enhancing targeted drug delivery in applications such as antibody-drug conjugates and cell and gene therapies. Established in 1998 and originally named Pharmacophorix Limited, Isogenica serves pharmaceutical and biotechnology sectors, contributing significantly to advancements in medical research and therapeutic development.